Clinical efficacy of Xialiqi capsule combined with tamsulosin sustained-release capsule in the treatment of benign prostate hyperplasia
TIAN Ning-ning,LIU BO,ZHANG Qing-jiao
Tianjin Fourth Central Hospital,Tianjing(300241),China
Abstract:
Objective To investigate the efficacy and safety of traditional Chinese medicine Xialiqi capsule combined with Tamsulosin hydrochloride sustained-release capsule in the treatment of patients with prostatic hyperplasia. Methods The study included a total of 76 patients diagnosed with benign prostatic hyperplasia who were admitted to the outpatient department of the Second Hospital of Tianjin Medical University from May 8, 2021, to November 30, 2022. They were randomly assigned into two groups:the experimental group received Xialiqi capsule (1.35 g, three times daily) in combination with tamsulosin sustained-release capsule (0.2 mg, taken before bedtime); the control group received only tamsulosin sustained-release capsule (0.2 mg, taken before bedtime). After an eight-week treatment period following their respective medication regimens, statistical analysis was conducted to compare and analyze the differences in international prostate symptom score (I-PSS), syndrome score of traditional Chinese medicine, maximum urinary flow rate (Qmax), prostate volume, residual urine volume, NIH-CPSI score and quality of life score (QOL) between the two groups before and after treatment. Furthermore, the effectiveness and safety of both medication regimens were evaluated. Results The main outcome measures: After treatment, both the I-PSS score and the syndrome score of traditional Chinese medicine in both groups showed significant decreases compared with those before treatment (P<0.05). The Qmax in the experimental group after treatment was greater than that in the control group (P=0.007), and the increase in the experimental group was significantly greater than that in the control group (P<0.001).The NIH-CPSI after treatment in the experimental group was significantly lower than that in the control group (P=0.044), and the difference in NIH-CPSI before and after treatment in the experimental group was larger than that in the control group (P=0.008). The overall efficacy rate of the experimental group was 94.7%, while that of the control group was 42.1%, with a significant statistical difference (P<0.001). Conclusion The efficacy of Xialiqi capsule combined with tamsulosin hydrochloride sustained-release capsule in the treatment of benign prostatic hyperplasia was significantly higher than that of the control group. No adverse events occurred in the two groups during the treatment, and the safety and compliance were good.
